According to DelveInsight, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017-2030)

  • PublishedJuly 29, 2022
According to DelveInsight, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017-2030)

Multiple Myeloma market size therapies will increase dramatically by 2030 due to the arrival of upcoming therapies that will carve out niche roles in the drug landscape. DelveInsight’s latest report on Multiple Myeloma Epidemiology and Market indicates that the impressive growth in market size is due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness and expected increase in investment in the R&D activities are some additional factors that are going to fuel the market.


Multiple Myeloma Overview

Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.


Download Sample Report-


Regions covered in the report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Key highlights of the Multiple Myeloma Market Report

  • In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
  • The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2030.
  • Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65–74 years has by far the most, followed by 75–84 years and 55–64 years.
  • In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.


Multiple Myeloma Epidemiology Segmentation in the 7MM

  • Total Multiple Myeloma Incident Cases
  • Total Multiple Myeloma Incident cases by Age Distribution
  • Total Symptomatic Multiple Myeloma Cases
  • Cases of Multiple Myeloma by Treatment Line
  • Gender-specific cases of Multiple Myeloma


Multiple Myeloma Marketed Drugs

  • Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
  • Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
  • Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
  • Sarclisa (Isatuximab): Sanofi
  • Xpovio (Selinexor): Karyopharm
  • Darzalex (Daratumumab): Janssen Biotech


Multiple Myeloma Emerging Drugs

  • Venetoclax (ABT-199): AbbVie and Roche
  • Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech
  • REGN5458: Regeneron Pharmaceuticals
  • Iberdomide (CC-220): Bristol-Myers Squibb/Celgene


Do you want to know more information related to the report? Click here-


Multiple myeloma Treatment Market

Multiple myeloma treatment includes stem cell transplant, conventional chemotherapy, targeted therapy, surgery, and radiation therapy. Chemotherapies can be given alone or in conjunction with other drugs including corticosteroids, proteasome inhibitors, immune-modulators, and monoclonal antibodies, anti-resorptive agents such as bisphosphonates and NSAIDs, or narcotics.  Currently, Lenalidomide is the market leader in multiple myeloma treatment landscape, and usage as monotherapy and also in combination with other therapies can be found across all the settings. Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly.


Multiple Myeloma Pipeline Therapies

  • Idecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bio
  • Venetoclax (Venclexta, Venclyxto): AbbVie
  • JNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and Development
  • Keytruda (pembrolizumab): Novartis
  • Melflufen (melphalan flufenamide): Oncopeptides
  • Cetrelimab (JNJ-63723283): Janssen Research and Development
  • REGN5458: Regeneron Pharmaceuticals
  • Iberdomide: Celgene
  • NY-ESO-1 C259 T Cells: GlaxoSmithKline
  • Braftovi (encorafenib): Pfizer
  • JCARH125: Celgene Corporation
  • Felzartamab (MOR202): I-Mab Biopharma
  • Chidamide (Epidaza): Shenzhen Chipscreen Bioscience


Multiple Myeloma Market Landscape

The past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times. Ongoing advancements in  emerging Novel therapies such as CAR-T cell and monoclonal antibodies are showing promising results in treating multiple myeloma patients and are also expected to drive the growth of the market.


Table of content

1. Key Insights

2. Multiple Myeloma Executive Summary

3. Competitive Intelligence Analysis for Multiple Myeloma

4. Multiple Myeloma: Market Overview at a Glance

5. Multiple Myeloma: Disease Background and Overview

6. Patient Journey

7. Multiple Myeloma Epidemiology and Patient Population

8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Myeloma Unmet Needs

10. Key Endpoints of Multiple Myeloma Treatment

11. Multiple Myeloma Marketed Products

12. Multiple Myeloma Emerging Therapies

13. Multiple Myeloma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Multiple Myeloma

17. KOL Views

18. Multiple Myeloma Market Drivers

19. Multiple Myeloma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Multiple Myeloma Market Report Scope

  • The report covers the descriptive overview of Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Multiple Myeloma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market.


Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market
  • To understand the future market competition in the Multiple Myeloma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma market
  • To understand the future market competition in the Multiple Myeloma market


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States